The polygenic risk score services market size has grown rapidly in recent years. It will grow from $1.24 billion in 2024 to $1.45 billion in 2025 at a compound annual growth rate (CAGR) of 16.9%. The growth in the historic period can be attributed to the increasing prevalence of chronic diseases, higher demand for personalized medicine, greater awareness of genetic predispositions, expanded availability of direct-to-consumer genetic testing, and growing adoption of genomic research in healthcare.
The polygenic risk score services market size is expected to see rapid growth in the next few years. It will grow to $2.68 billion in 2029 at a compound annual growth rate (CAGR) of 16.5%. The growth in the forecast period can be attributed to the rising use of artificial intelligence in genomics, increasing demand for preventive healthcare solutions, growing investment in genomic research and development, expanding integration of electronic health records with genetic data, and greater availability of polygenic risk score-based testing services. Key trends in the forecast period include technological improvements in polygenic risk score algorithms, innovations in multi-omics data integration, advances in ancestry-informed polygenic risk scoring, research on gene-environment interactions, and progress in pharmacogenomics applications.
The increasing focus on personalized medicine is expected to drive growth in the polygenic risk score services market. Personalized medicine involves tailoring prevention, diagnosis, and treatment based on an individual’s genetics, environment, and lifestyle factors. Advances in genomics have fueled the rise of personalized medicine by providing a deeper understanding of genetic variations, enabling more accurate and targeted therapies that enhance patient outcomes and reduce trial-and-error approaches. Polygenic risk score services support personalized medicine by evaluating multiple genetic variants to estimate a person’s likelihood of developing certain diseases. This allows healthcare providers to create customized prevention plans, early interventions, and treatment strategies based on each patient’s genetic information. For example, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit, reported that the FDA approved 16 new personalized therapies for rare diseases in 2023, an increase from six approvals in 2022. The 2023 approvals also included seven cancer drugs and three treatments for other conditions. This growing emphasis on personalized medicine is boosting demand for polygenic risk score services.
Leading companies in the polygenic risk score services market are developing advanced solutions such as pharmacogenomics to improve personalized treatment approaches and patient outcomes. Pharmacogenomics studies how a person’s genetic makeup affects their response to medications, facilitating more precise and individualized therapies. For instance, in July 2025, Bupa, a UK-based health insurer, launched a series of DNA-based tests offering personalized insights on medication response and disease risk. These tests enable earlier detection and tailored management of conditions including cancer, diabetes, and cardiovascular disease. They aim to reduce side effects, improve long-term health, and empower individuals to actively manage their health and that of their families. This reflects a shift from reactive treatment toward preventive, precision healthcare.
In May 2024, GSK Plc, a UK pharmaceutical company, formed a partnership with Genomics Ltd. to advance genetic research and develop personalized treatments. The collaboration focuses on utilizing polygenic risk scores to improve clinical trial design by selecting appropriate patient groups, reducing trial size and duration, and increasing the efficiency of drug development. Genomics Ltd. is a UK-based company specializing in polygenic risk score services within precision medicine.
Major players in the polygenic risk score services market are Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Illumina Inc., Endeavor Health Inc., Myriad Genetics Inc., The Broad Institute of MIT and Harvard, BGI Group, Invitae Corporation, 23andMe Holding Co., Color Health Inc., Genomics Ltd., Cogentech S.R.L., Gene by Gene Ltd., Our Future Health Ltd., Mapmygenome India Limited, Australian Genome Research Facility (AGRF) Ltd., Golden Helix Inc., Allelica Inc., Antegenes OÜ, GeninCode Plc.
North America was the largest region in the polygenic risk score services market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in polygenic risk score (PRS) services report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the polygenic risk score (PRS) services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.
Polygenic risk score (PRS) services are solutions that estimate an individual’s probability of developing specific diseases or conditions based on the combined impact of multiple genetic variants across the genome. These services analyze DNA data, typically obtained through genotyping or sequencing, and use statistical models to produce a risk score.
The primary service types of polygenic risk score services are genotyping, sequencing, data analysis, reporting, and others. Genotyping involves identifying variations in an individual’s genetic makeup (genotype) by examining their DNA sequence using biological assays. These services are applied in areas such as disease risk assessment, personalized medicine, research, and others, and are utilized by key end-users including hospitals and clinics, research institutions, direct-to-consumer providers, and others.
The polygenic risk score services market research report is one of a series of new reports that provides polygenic risk score services market statistics, including polygenic risk score services industry global market size, regional shares, competitors with a polygenic risk score services market share, detailed polygenic risk score services market segments, market trends and opportunities, and any further data you may need to thrive in the polygenic risk score services industry. This polygenic risk score services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The polygenic risk score (PRS) services market includes revenues earned by entities providing services such as polygenic risk scoring, genetic testing, data analysis and interpretation services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The polygenic risk score services market size is expected to see rapid growth in the next few years. It will grow to $2.68 billion in 2029 at a compound annual growth rate (CAGR) of 16.5%. The growth in the forecast period can be attributed to the rising use of artificial intelligence in genomics, increasing demand for preventive healthcare solutions, growing investment in genomic research and development, expanding integration of electronic health records with genetic data, and greater availability of polygenic risk score-based testing services. Key trends in the forecast period include technological improvements in polygenic risk score algorithms, innovations in multi-omics data integration, advances in ancestry-informed polygenic risk scoring, research on gene-environment interactions, and progress in pharmacogenomics applications.
The increasing focus on personalized medicine is expected to drive growth in the polygenic risk score services market. Personalized medicine involves tailoring prevention, diagnosis, and treatment based on an individual’s genetics, environment, and lifestyle factors. Advances in genomics have fueled the rise of personalized medicine by providing a deeper understanding of genetic variations, enabling more accurate and targeted therapies that enhance patient outcomes and reduce trial-and-error approaches. Polygenic risk score services support personalized medicine by evaluating multiple genetic variants to estimate a person’s likelihood of developing certain diseases. This allows healthcare providers to create customized prevention plans, early interventions, and treatment strategies based on each patient’s genetic information. For example, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit, reported that the FDA approved 16 new personalized therapies for rare diseases in 2023, an increase from six approvals in 2022. The 2023 approvals also included seven cancer drugs and three treatments for other conditions. This growing emphasis on personalized medicine is boosting demand for polygenic risk score services.
Leading companies in the polygenic risk score services market are developing advanced solutions such as pharmacogenomics to improve personalized treatment approaches and patient outcomes. Pharmacogenomics studies how a person’s genetic makeup affects their response to medications, facilitating more precise and individualized therapies. For instance, in July 2025, Bupa, a UK-based health insurer, launched a series of DNA-based tests offering personalized insights on medication response and disease risk. These tests enable earlier detection and tailored management of conditions including cancer, diabetes, and cardiovascular disease. They aim to reduce side effects, improve long-term health, and empower individuals to actively manage their health and that of their families. This reflects a shift from reactive treatment toward preventive, precision healthcare.
In May 2024, GSK Plc, a UK pharmaceutical company, formed a partnership with Genomics Ltd. to advance genetic research and develop personalized treatments. The collaboration focuses on utilizing polygenic risk scores to improve clinical trial design by selecting appropriate patient groups, reducing trial size and duration, and increasing the efficiency of drug development. Genomics Ltd. is a UK-based company specializing in polygenic risk score services within precision medicine.
Major players in the polygenic risk score services market are Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Illumina Inc., Endeavor Health Inc., Myriad Genetics Inc., The Broad Institute of MIT and Harvard, BGI Group, Invitae Corporation, 23andMe Holding Co., Color Health Inc., Genomics Ltd., Cogentech S.R.L., Gene by Gene Ltd., Our Future Health Ltd., Mapmygenome India Limited, Australian Genome Research Facility (AGRF) Ltd., Golden Helix Inc., Allelica Inc., Antegenes OÜ, GeninCode Plc.
North America was the largest region in the polygenic risk score services market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in polygenic risk score (PRS) services report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the polygenic risk score (PRS) services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.
Polygenic risk score (PRS) services are solutions that estimate an individual’s probability of developing specific diseases or conditions based on the combined impact of multiple genetic variants across the genome. These services analyze DNA data, typically obtained through genotyping or sequencing, and use statistical models to produce a risk score.
The primary service types of polygenic risk score services are genotyping, sequencing, data analysis, reporting, and others. Genotyping involves identifying variations in an individual’s genetic makeup (genotype) by examining their DNA sequence using biological assays. These services are applied in areas such as disease risk assessment, personalized medicine, research, and others, and are utilized by key end-users including hospitals and clinics, research institutions, direct-to-consumer providers, and others.
The polygenic risk score services market research report is one of a series of new reports that provides polygenic risk score services market statistics, including polygenic risk score services industry global market size, regional shares, competitors with a polygenic risk score services market share, detailed polygenic risk score services market segments, market trends and opportunities, and any further data you may need to thrive in the polygenic risk score services industry. This polygenic risk score services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The polygenic risk score (PRS) services market includes revenues earned by entities providing services such as polygenic risk scoring, genetic testing, data analysis and interpretation services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Polygenic Risk Score Services Market Characteristics3. Polygenic Risk Score Services Market Trends and Strategies32. Global Polygenic Risk Score Services Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Polygenic Risk Score Services Market34. Recent Developments in the Polygenic Risk Score Services Market
4. Polygenic Risk Score Services Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, and Covid and Recovery on the Market
5. Global Polygenic Risk Score Services Growth Analysis and Strategic Analysis Framework
6. Polygenic Risk Score Services Market Segmentation
7. Polygenic Risk Score Services Market Regional and Country Analysis
8. Asia-Pacific Polygenic Risk Score Services Market
9. China Polygenic Risk Score Services Market
10. India Polygenic Risk Score Services Market
11. Japan Polygenic Risk Score Services Market
12. Australia Polygenic Risk Score Services Market
13. Indonesia Polygenic Risk Score Services Market
14. South Korea Polygenic Risk Score Services Market
15. Western Europe Polygenic Risk Score Services Market
16. UK Polygenic Risk Score Services Market
17. Germany Polygenic Risk Score Services Market
18. France Polygenic Risk Score Services Market
19. Italy Polygenic Risk Score Services Market
20. Spain Polygenic Risk Score Services Market
21. Eastern Europe Polygenic Risk Score Services Market
22. Russia Polygenic Risk Score Services Market
23. North America Polygenic Risk Score Services Market
24. USA Polygenic Risk Score Services Market
25. Canada Polygenic Risk Score Services Market
26. South America Polygenic Risk Score Services Market
27. Brazil Polygenic Risk Score Services Market
28. Middle East Polygenic Risk Score Services Market
29. Africa Polygenic Risk Score Services Market
30. Polygenic Risk Score Services Market Competitive Landscape and Company Profiles
31. Polygenic Risk Score Services Market Other Major and Innovative Companies
35. Polygenic Risk Score Services Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Polygenic Risk Score Services Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on polygenic risk score services market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for polygenic risk score services? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The polygenic risk score services market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:
1) By Service Type: Genotyping; Sequencing; Data Analysis; Reporting; Other Service Types2) By Application: Disease Risk Assessment; Personalized Medicine; Research; Other Applications
3) By End-User: Hospitals And Clinics; Research Institutes; Direct-to-Consumer; Other End-Users
Subsegments:
1) By Genotyping: Array-Based Genotyping; Targeted Genotyping; High-Throughput Genotyping2) By Sequencing: Whole Genome Sequencing (Wgs); Whole Exome Sequencing (Wes); Targeted Sequencing
3) By Data Analysis: Polygenic Risk Prediction Algorithms; Bioinformatics And Statistical Analysis; Data Integration With Electronic Health Records (Ehr)
4) By Reporting: Clinical Reports For Healthcare Providers; Direct-To-Consumer (Dtc) Reports; Risk Stratification Reports (Disease-Specific)
5) By Other Service Types: Genetic Counseling Services; Data Storage And Cloud-Based Platforms; Prs Software And Toolkits
Companies Mentioned: Thermo Fisher Scientific Inc.; Laboratory Corporation of America Holdings; Illumina Inc.; Endeavor Health Inc.; Myriad Genetics Inc.; The Broad Institute of MIT and Harvard; BGI Group; Invitae Corporation; 23andMe Holding Co.; Color Health Inc.; Genomics Ltd.; Cogentech S.R.L.; Gene by Gene Ltd.; Our Future Health Ltd.; Mapmygenome India Limited; Australian Genome Research Facility (AGRF) Ltd.; Golden Helix Inc.; Allelica Inc.; Antegenes OÜ; GeninCode Plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The companies featured in this Polygenic Risk Score Services market report include:- Thermo Fisher Scientific Inc.
- Laboratory Corporation of America Holdings
- Illumina Inc.
- Endeavor Health Inc.
- Myriad Genetics Inc.
- The Broad Institute of MIT and Harvard
- BGI Group
- Invitae Corporation
- 23andMe Holding Co.
- Color Health Inc.
- Genomics Ltd.
- Cogentech S.R.L.
- Gene by Gene Ltd.
- Our Future Health Ltd.
- Mapmygenome India Limited
- Australian Genome Research Facility (AGRF) Ltd.
- Golden Helix Inc.
- Allelica Inc.
- Antegenes OÜ
- GeninCode Plc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | October 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 1.45 Billion |
| Forecasted Market Value ( USD | $ 2.68 Billion |
| Compound Annual Growth Rate | 16.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
